MA53511B1 - Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée - Google Patents

Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée

Info

Publication number
MA53511B1
MA53511B1 MA53511A MA53511A MA53511B1 MA 53511 B1 MA53511 B1 MA 53511B1 MA 53511 A MA53511 A MA 53511A MA 53511 A MA53511 A MA 53511A MA 53511 B1 MA53511 B1 MA 53511B1
Authority
MA
Morocco
Prior art keywords
long
treatment regime
acting injectable
missed doses
injectable paliperidone
Prior art date
Application number
MA53511A
Other languages
English (en)
Other versions
MA53511A (fr
Inventor
Srihari Gopal
Paulien Gerarda Maria Ravenstijn
Alberto Russu
Mahesh Narain Samtani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/US2016/024841 external-priority patent/WO2016164218A1/fr
Publication of MA53511A publication Critical patent/MA53511A/fr
Publication of MA53511B1 publication Critical patent/MA53511B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode de traitement de patients nécessitant un traitement psychiatrique, ledit patient étant traité avec la formulation de palmitate de palipéridone pour 3 mois et ne prenant pas la dose programmée suivante de la formulation de palmitate de palipéridone pour 3 mois.
MA53511A 2015-04-07 2016-03-30 Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée MA53511B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
PCT/US2016/024841 WO2016164218A1 (fr) 2015-04-07 2016-03-30 Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée

Publications (2)

Publication Number Publication Date
MA53511A MA53511A (fr) 2021-09-15
MA53511B1 true MA53511B1 (fr) 2023-12-29

Family

ID=89428893

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53511A MA53511B1 (fr) 2015-04-07 2016-03-30 Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée

Country Status (1)

Country Link
MA (1) MA53511B1 (fr)

Also Published As

Publication number Publication date
MA53511A (fr) 2021-09-15

Similar Documents

Publication Publication Date Title
MA41917B1 (fr) Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée
AR101740A1 (es) Terapia de combinación y composiciones
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
MX2017006823A (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreina plasmatica.
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
MX379286B (es) INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
MX388641B (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
CY1125499T1 (el) Εστερες αζελαϊκου οξεος στη θεραπεια της αντιστασης στην ινσουλινη
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
ZA202400851B (en) Dosing regimens associated with extended release paliperidone injectable formulations
MX2024009188A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2023006368A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
CY1120075T1 (el) Καρβορανυλο-πορφυρινες για χρηση στη θεραπεια του καρκινου
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA201992414A1 (ru) Комбинация nk1-антагониста и способ лечения синуклеинопатий
MA53511B1 (fr) Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée
MX2022005245A (es) Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer.
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica